Mikael Dolsten, Pfizer's former research and development chief, has withdrawn his candidacy for Novo Nordisk's board, citing ...

(Reuters) -Mikael Dolsten, Pfizer's former research and development chief, has withdrawn his candidacy for Novo Nordisk's ...

Mikael Dolsten, the longtime Pfizer executive who led the companys research and development operations, has withdrawn his ...

The executive, who brought Novo’s first weight-loss shot to market, had to spend part of the meeting explaining why proposed ...

Shareholders will vote Friday on the appointment of Lars Rebien Sorensen as chair, Cees de Jong as vice chair, and Britt Meelby Jensen and Stephan Engels as board members. Current board members Kasim ...

Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary ...

Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity ...

The executive who brought Novo Nordisk A/S’s first weight-loss shot to market is coming back as chairman of the Danish ...

Novo Nordisk’s board overhaul signals a decisive return to Foundation-led scientific and operational governance, raising strategic questions about whether the company can sustain U.S. growth and ...

On Friday, Cees de Jong was named vice chair, replacing Henrik Poulsen. Britt Meelby Jensen and Stephan Engels were appointed as new board members. The company plans to seek the election of Helena ...

Novo Nordisk has found itself in an increasingly chaotic situation as of late, with shares plunging and investor confidence ...